查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1941887

癌症疫苗市場規模、佔有率和趨勢分析報告：按疫苗類型、適應症類型、技術類型、地區和細分市場預測（2026-2033 年）

Cancer Vaccine Market Size, Share & Trends Analysis Report By Vaccine Type (Preventive Cancer Vaccine, Therapeutic Cancer Vaccine), By Indication Type, By Technology Type, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

癌症疫苗市場概況

2025年全球癌症疫苗市場規模估計為99.3億美元，預計2033年將達到233.1億美元。

預計從 2026 年到 2033 年，該市場將以 11.30% 的複合年成長率成長。這一成長主要受全球癌症負擔加重、免疫治療方法的廣泛應用以及疫苗技術（如 mRNA、樹突細胞平台和個人化新抗原疫苗）的快速發展所驅動。

由於全球癌症負擔日益加重，以及人們對免疫療法作為長期治療方案的興趣日益濃厚，癌症疫苗產業正在迅速擴張。 mRNA和DNA平台等疫苗技術的進步，顯著提高了疫苗設計能力，使疫苗能夠比傳統治療方法更有效地誘導免疫系統識別特異性抗原並摧毀癌細胞。

人們對癌症疫苗的興趣日益濃厚，尤其是在治療選擇有限的固體癌領域。這主要得益於製藥公司和學術研究機構加大投入，尋求能夠減少副作用並改善患者預後的個人化療法。例如，2026年1月有報告指出，Moderna和默克聯合研發的個人化癌症疫苗與Keytruda合併使用，在長期追蹤中，高風險黑色素瘤患者的復發或死亡風險顯著降低。這項發現增強了人們對疫苗療法的信心，並推動了進一步的臨床研發和資金籌措。

癌症疫苗產業的另一個成長要素是科學技術創新的快速發展，這些創新提高了候選疫苗的準確性和有效性。抗原辨識、新型抗原標標靶化和計算生物學等新技術，使得針對個別腫瘤獨特基因譜客製化疫苗的研發成為可能，這對於激發強效的免疫反應至關重要。不斷擴展的臨床試驗計畫表明，研究人員和投資者對癌症疫苗在多種癌症類型（包括傳統上難以治療的癌症）中取得顯著療效的潛力越來越有信心。

例如，2025年7月，佛羅裡達大學的研究人員開發出一種實驗性mRNA疫苗，該疫苗在臨床前模型中誘發了針對腫瘤的強效抗癌免疫反應。這項成果凸顯了下一代疫苗的潛力以及支撐市場成長的技術發展勢頭。

市場成長也得益於有利的政策環境、意識提升，以及新型診斷工具與疫苗策略的結合。各國政府和衛生組織正在加大對免疫療法研究的投入，生技公司與研究機構的合作也日益增加。這些因素正在加速產品開發和監管核准流程。

此外，新冠疫情期間疫苗平台的成功應用增強了人們對mRNA技術在其他疾病（包括癌症）治療方面的信心，從而推動了投資成長，並加速了研究成果向臨床應用的轉化。例如，俄羅斯於2025年9月宣布，其採用先進mRNA技術研發的新型癌症疫苗Enteromix將在獲得監管部門核准後投入臨床使用，並免費提供給患者。這正是技術進步和政策支持共同推動市場擴張的例子。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：癌症疫苗市場的變數、趨勢和範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章：癌症疫苗市場：按疫苗類型分類的業務分析

  • 按疫苗類型分類的市場佔有率（2025 年和 2033 年）
  • 按疫苗類型分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 預防性癌症疫苗
  • 用於治療的癌症疫苗
  • 其他

第5章：癌症疫苗市場：按適應症類型分類的業務分析

  • 按適應症類型分類的市場佔有率（2025 年和 2033 年）
  • 按適應症類型分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 攝護腺癌
  • 膀胱癌
  • 惡性黑色素瘤
  • 子宮頸癌
  • 其他

第6章：癌症疫苗市場：按技術類型分類的業務分析

  • 按技術類型分類的市場佔有率（2025 年和 2033 年）
  • 按技術類型分類的市場規模、預測與趨勢分析（2021年至2033年）
  • 重組癌症疫苗
  • 全細胞癌症疫苗
  • 病毒載體和DNA癌症疫苗
  • 其他技術

第7章：癌症疫苗市場：區域估算與趨勢分析

  • 區域市場佔有率分析（2025 年和 2033 年）
  • 區域市場概覽
  • 2021年至2033年市場規模及預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 參與企業概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • Merck &Co., Inc.
    • GSK plc
    • Dendreon Pharmaceuticals LLC.
    • Dynavax Technologies.
    • Ferring BV
    • Amgen, Inc.
    • Moderna, Inc.
    • Sanofi
    • AstraZeneca
    • Bristol-Myers Squibb Company
Product Code: GVR-4-68040-096-2

Cancer Vaccine Market Summary

The global cancer vaccine market size was estimated at USD 9.93 billion in 2025 and is projected to reach USD 23.31 billion by 2033, growing at a CAGR of 11.30% from 2026 to 2033. This growth is primarily driven by the rising global burden of cancer, increasing adoption of immunotherapy-based treatments, and rapid advancements in vaccine technologies such as mRNA, dendritic cell platforms, and personalized neoantigen vaccines.

The Cancer Vaccine industry is expanding rapidly because of the rising global burden of cancer and the increasing emphasis on immunotherapy as a viable long-term treatment option. Advances in vaccine technology, such as mRNA and DNA platforms, have significantly improved the ability to design vaccines that teach the immune system to recognize cancer-specific antigens and destroy tumor cells more effectively than traditional therapies.

Interest in Cancer Vaccine has been bolstered by growing investment from pharmaceutical companies and academic research groups seeking more personalized treatments that can reduce side effects and improve patient outcomes, especially in solid tumors where options remain limited. For instance, in January 2026, Moderna and Merck reported that their personalized cancer vaccine used with Keytruda showed a sustained reduction in risk of recurrence or death in high-risk melanoma patients during long-term follow-up, reinforcing confidence in vaccine approaches and driving further clinical development and funding.

Another major growth factor in the Cancer Vaccine industry is the rapid pace of scientific innovation improving the precision and effectiveness of vaccine candidates. New techniques in antigen identification, neoantigen targeting, and computational biology have enabled vaccines to be tailored to the unique genetic profile of individual tumors, which is critical for triggering a robust immune response. The expanding pipeline of clinical trials demonstrates increasing confidence among researchers and investors that Cancer Vaccine can deliver meaningful benefits across multiple cancer types, including those historically difficult to treat.

For instance, in July 2025, Scientists at the University of Florida developed an experimental mRNA vaccine that triggered a strong anticancer immune response against tumors in preclinical models, highlighting both the promise of next-generation vaccines and the technological momentum supporting market growth.

Market growth is also propelled by supportive policy environments, increasing public awareness of cancer prevention and early detection, and the integration of novel diagnostic tools that work in tandem with vaccine strategies. Governments and health agencies have intensified funding for immunotherapy research, and collaborations between biotech firms and research institutions are becoming more common, which accelerates product development and regulatory approval pathways.

Moreover, the success of vaccine platforms during the COVID-19 pandemic has reinforced confidence in mRNA technology for other diseases, including cancer, leading to greater investment and quicker translation of research into clinical applications. For instance, in September 2025, Russia announced that its new cancer vaccine Enteromix, developed using advanced mRNA technology, was ready for clinical use and would be provided free to patients following regulatory approval, illustrating both the technological progress and policy support driving market expansion.

Global Cancer Vaccine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Cancer Vaccine market report based on vaccine type, indication type, technology type, and region:

  • Vaccine Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Preventive Cancer Vaccine
  • Therapeutic Cancer Vaccine
  • Others
  • Indication Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Prostate Cancer
  • Bladder Cancer
  • Melanoma
  • Cervical Cancer
  • Other
  • Technology Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Recombinant Cancer Vaccine
  • Whole-cell Cancer Vaccine
  • Viral Vector and DNA Cancer Vaccine
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Vaccine Type
    • 1.2.2. Indication Type
    • 1.2.3. Technology Type
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Cancer Vaccine Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Cancer Vaccine Market: Vaccine Type Business Analysis

  • 4.1. Vaccine Type Market Share, 2025 & 2033
  • 4.2. Vaccine Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Vaccine Type, 2021 to 2033 (USD Million)
  • 4.4. Preventive Cancer Vaccine
    • 4.4.1. Preventive Cancer Vaccine Market, 2021 - 2033 (USD Million)
  • 4.5. Therapeutic Cancer Vaccine
    • 4.5.1. Therapeutic Cancer Vaccine Market, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Cancer Vaccine Market: Indication Type Business Analysis

  • 5.1. Indication Type Market Share, 2025 & 2033
  • 5.2. Indication Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication Type, 2021 to 2033 (USD Million)
  • 5.4. Prostate Cancer
    • 5.4.1. Prostate Cancer Market, 2021 - 2033 (USD Million)
  • 5.5. Bladder Cancer
    • 5.5.1. Bladder Cancer Market, 2021 - 2033 (USD Million)
  • 5.6. Melanoma
    • 5.6.1. Melanoma Market, 2021 - 2033 (USD Million)
  • 5.7. Cervical Cancer
    • 5.7.1. Cervical Cancer Market, 2021 - 2033 (USD Million)
  • 5.8. Other
    • 5.8.1. Other Market, 2021 - 2033 (USD Million)

Chapter 6. Cancer Vaccine Market: Technology Type Business Analysis

  • 6.1. Technology Type Market Share, 2025 & 2033
  • 6.2. Technology Type Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by technology type, 2021 to 2033 (USD Million)
  • 6.4. Recombinant Cancer Vaccine
    • 6.4.1. Recombinant Cancer Vaccine Market, 2021 - 2033 (USD Million)
  • 6.5. Whole-cell Cancer Vaccine
    • 6.5.1. Whole-cell Cancer Vaccine Market, 2021 - 2033 (USD Million)
  • 6.6. Viral Vector and DNA Cancer Vaccine
    • 6.6.1. Viral Vector and DNA Cancer Vaccine Market, 2021 - 2033 (USD Million)
  • 6.7. Other Technologies
    • 6.7.1. Other Technologies Market, 2021 - 2033 (USD Million)

Chapter 7. Cancer Vaccine Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Cancer Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Technology Type Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Technology Type Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Technology Type Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Technology Type Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Technology Type Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Technology Type Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Technology Type Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Technology Type Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Technology Type Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Technology Type Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Technology Type Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Technology Type Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Technology Type Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Technology Type Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Technology Type Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Technology Type Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Technology Type Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Technology Type Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Technology Type Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Technology Type Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Technology Type Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Technology Type Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Technology Type Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Merck & Co., Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. GSK plc
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Dendreon Pharmaceuticals LLC.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Dynavax Technologies.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Ferring B.V.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Amgen, Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Moderna, Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Sanofi
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. AstraZeneca
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Bristol-Myers Squibb Company
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Cancer Vaccine market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 5 Global Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 6 Global Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 7 North America Cancer Vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 9 North America Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 10 North America Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 11 U.S. Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 12 U.S. Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 13 U.S. Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 14 Canada Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 15 Canada Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 16 Canada Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 17 Mexico Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 18 Mexico Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 19 Mexico Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 20 Europe Cancer Vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 22 Europe Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 23 Europe Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 24 UK Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 25 UK Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 26 UK Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 27 Germany Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 28 Germany Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 29 Germany Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 30 France Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 31 France Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 32 France Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 33 Italy Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 34 Italy Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 35 Italy Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 36 Spain Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 37 Spain Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 38 Spain Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 39 Norway Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 40 Norway Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 41 Norway Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 42 Denmark Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 43 Denmark Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 44 Denmark Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 45 Sweden Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 46 Sweden Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 47 Sweden Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Cancer Vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Cancer Vaccine market, by indication type, 2021 - 2033 (USD
  • Table 51 Asia Pacific Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 52 Japan Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 53 Japan Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 54 Japan Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 55 China Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 56 China Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 57 China Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 58 India Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 59 India Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 60 India Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 61 Australia Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 62 Australia Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 63 Australia Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 64 South Korea Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 65 South Korea Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 66 South Korea Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 67 Thailand Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 68 Thailand Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 69 Thailand Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 70 Latin America Cancer Vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 72 Latin America Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 73 Latin America Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 74 Brazil Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 75 Brazil Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 76 Brazil Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 77 Argentina Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 78 Argentina Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 79 Argentina Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa Cancer Vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 84 South Africa Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 85 South Africa Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 86 South Africa Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 90 UAE Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 91 UAE Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 92 UAE Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Cancer Vaccine market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Cancer Vaccine market dynamics
  • Fig. 11 Cancer Vaccine market: Porter's five forces analysis
  • Fig. 12 Cancer Vaccine market: PESTLE analysis
  • Fig. 13 Vaccine Type market, 2021 - 2033 (USD Million)
  • Fig. 14 Preventive Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 15 Therapeutic Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 16 Others market, 2021 - 2033 (USD Million)
  • Fig. 17 Indication Type market, 2021 - 2033 (USD Million)
  • Fig. 18 Prostate Cancer market, 2021 - 2033 (USD Million)
  • Fig. 19 Bladder Cancer market, 2021 - 2033 (USD Million)
  • Fig. 20 Melanoma market, 2021 - 2033 (USD Million)
  • Fig. 21 Cervical Cancer market, 2021 - 2033 (USD Million)
  • Fig. 22 Other market, 2021 - 2033 (USD Million)
  • Fig. 23 Technology Type market, 2021 - 2033 (USD Million)
  • Fig. 24 Recombinant Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 25 Whole-cell Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 26 Viral Vector and DNA Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 27 Other Technologies market, 2021 - 2033 (USD Million)
  • Fig. 28 Cancer Vaccine market revenue, by region
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 North America Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. country dynamics
  • Fig. 32 U.S. Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 33 Canada country dynamics
  • Fig. 34 Canada Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 35 Mexico country dynamics
  • Fig. 36 Mexico Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 37 Europe Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 38 UK country dynamics
  • Fig. 39 UK Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 40 Germany country dynamics
  • Fig. 41 Germany Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 42 France country dynamics
  • Fig. 43 France Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 44 Italy country dynamics
  • Fig. 45 Italy Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 46 Spain country dynamics
  • Fig. 47 Spain Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 48 Norway country dynamics
  • Fig. 49 Norway Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 50 Sweden country dynamics
  • Fig. 51 Sweden Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 52 Denmark country dynamics
  • Fig. 53 Denmark Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 54 Asia Pacific Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 55 Japan country dynamics
  • Fig. 56 Japan Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 57 China country dynamics
  • Fig. 58 China Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 59 India country dynamics
  • Fig. 60 India Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 61 Australia country dynamics
  • Fig. 62 Australia Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 63 South Korea country dynamics
  • Fig. 64 South Korea Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 65 Thailand country dynamics
  • Fig. 66 Thailand Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 67 Latin America Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 68 Brazil country dynamics
  • Fig. 69 Brazil Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 70 Argentina country dynamics
  • Fig. 71 Argentina Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 72 MEA Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 73 South Africa country dynamics
  • Fig. 74 South Africa Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 75 Saudi Arabia country dynamics
  • Fig. 76 Saudi Arabia Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 77 UAE country dynamics
  • Fig. 78 UAE Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 79 Kuwait country dynamics
  • Fig. 80 Kuwait Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 81 Company categorization
  • Fig. 82 Company market position analysis
  • Fig. 83 Strategic framework